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One important modality of breast cancer therapy is surgical treatment, which has become increasingly
less mutilating over the last century. Breast reconstruction has become an integrated part of breast
cancer treatment due to long-term psychosexual health factors and its importance for breast cancer
survivors. Both autogenous tissue-based and implant-based reconstruction provides satisfactory recon-
structive options due to better surgeon awareness of “the ideal breast size”, although each has its own
advantages and disadvantages. An overview of the current options in breast reconstruction is presented
in this article.
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Breast cancer is the leading cause of cancer death among
women worldwide, with approximately 1.7 million new diagnoses
and 521,900 deaths occurring in 2012 [1]. One important modality
of breast cancer therapy is surgical treatment, which has become
increasingly less mutilating over the last century. Approximately
35e40% of women diagnosed with breast cancer undergo total
mastectomy, a trend that is increasing [2]. Until the 1970s, breast
cancer was treated with radical mastectomy involving removal of
the breast, axillary lymph nodes, and pectoralis muscle. This was
extremely disﬁguring for patients and did not lend itself to optimal
reconstructive options. In the 1970s, modiﬁed radical mastectomy
was introduced, which preserved the pectoralis muscle and
improved the contour of the chest wall, as well as increased the
reconstructive possibilities. In the 1980s, a large randomized study
conducted by the National Surgical Adjuvant Breast and Bowel
Project (NSABP) demonstrated that breast conservation plus radi-
ation had equivalent outcome to mastectomy [3].
Breast reconstruction has become an integrated part of breast
cancer treatment due to long-term psychosexual health factors and
its importance for breast cancer survivors [4e6]. Both autogenous
tissue-based and implant-based reconstruction provides satisfac-
tory reconstructive options due to better surgeon awareness of “the
ideal breast size” [7], although each has its own advantages and
disadvantages. Data from the United States indicate that between
1998 and 2008, therewas an 11% increase in the use of implants per
year, whereas autologous reconstruction rates remained stable
[8,9]. Indeed, the data shows that prior to 2002, autologous re-
constructions were more frequently chosen compared with pros-
theses. However, after 2002, this relationship was reversed, and in
2008, implants outnumbered autologous reconstructions by a ratio
of 2:1 (258 vs. 120 per 1000 mastectomies) [8]. Albornoz et al. [8]
suggests a number of reasons behind this change: the longer time
it takes to perform autologous reconstruction, a cultural shift to-
wards acceptance of breast implants, and the way in which
reconstruction is funded. In alloplastic reconstructions, patients are
exposed to less surgical risk, fewer scars, less donor site morbidity,
and fewer irreversible consequences. However, surgical factors like
implant type, number of surgical stages, and the use of an acellular
dermal matrix can inﬂuence outcomes [10e13].
The authors analyze the current literature on the light of their
multicentric experience in the ﬁled of breast surgery in order to
determine the latest trends in breast reconstruction.
2. Mastectomy: different techniques
Themastectomy procedure has evolved from the Halsted radical
mastectomy, which involved a wide excision of all breast tissue, alloverlying skin, and the pectoralis major muscle and included a full
en bloc dissection of Level I, II, and III nodes [14]. The most
commonly performed mastectomy is the total mastectomy, which
removes all breast tissue including the nippleeareola complex
(NAC) and an ellipse of skin adjacent to the nippleeareola complex.
For women who require mastectomy for the surgical manage-
ment of breast cancer or as a prophylactic procedure in those with a
known genetic predisposition for breast cancer, skin-sparing mas-
tectomy with immediate reconstruction is an excellent choice that
allows complete breast parenchyma resection with acceptable
breast mound provision via an implant or ﬂap. This procedure
preserves as much of the patient's breast skin as possibledthe
breast parenchyma and nippleeareola complex are removed
through a circumareolar incision (sentinel lymph node dissection
may be performed through a separate incision if indicated). Skin-
sparing mastectomy has been shown to have equivalent local
recurrence rates to conventional mastectomy given the selection
bias of reserving this approach for patients without clinical evi-
dence of locally advanced or inﬂammatory breast cancer [15e18].
Another surgical option is nipple-sparing mastectomy, which
involves a total mastectomy via a noncentral incision (such as an
inframammary or axillary approach), preserving the skin, skin en-
velope, and cutaneous portion of the nippleeareola complex.
Crowe et al. published one of the ﬁrst modern series on this tech-
nique, reporting the technical feasibility of nipple-sparing mas-
tectomy [19] (Figs. 1e3).
3. Implants
Use of prosthetic implants for breast reconstruction began in the
early 1960s when Cronin and Gerow developed the silicone pros-
thesis and used it clinically for augmentation mammoplasty [20].
Shortly thereafter, these implants began to be used for the recon-
struction of mastectomized breasts [21]. Breast reconstructions
using prosthetic implants were applied in a single stage at ﬁrst.
Development of tissue expanders by Radovan created new possi-
bilities in immediate or delayed reconstruction, and the popularity
of single-stage reconstruction by implants was overtaken by two-
stage reconstructions during the 1980s [22].
The use of implants and skin expanders are the quickest and
presumably easiest methods of breast reconstruction. The prereq-
uisite for implant-based breast reconstruction is an adequate skin
envelope to cover the implant that is usually introduced into the
submuscular plane by detaching the medial insertions of the pec-
toralis major muscle from the ribs. Saline and silicone gel implants
are available as the ﬁnal implant material for expander/implant-
based postmastectomy reconstruction. All implant models have a
bladder (or outside shell) made of solid silicone. The shell can be
either textured or smooth. Modern expanders are textured to help
Fig. 1. Bilateral nipple-sparing mastectomy, preoperative design.
Fig. 2. Periareolar skin incision.
Fig. 3. All breast tissue removed.
Fig. 4. Textured implant.
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develop a well-deﬁned inframammary fold and ptosis [23]
(Figs. 4e7). Both saline and silicone implants can be either round
or anatomically shaped (like a teardrop). The consensus is that
there is no difference between round and shaped implants in
rippling or in overall satisfaction with breast surgery outcome
[24,25]. Silicone gel implants are traditionally thought to provide a
softer, more natural feeling breast compared with saline implants
[26].
4. Use of an acellular dermal matrix
Traditional submuscular placement of a tissue expander re-
quires the elevation of, and coverage with, the pectoralis major and
serratus anterior muscles. However, the use of an acellular dermal
matrix (ADM) has been increasing [27], with the pectoralis muscle
being used to cover the prosthesis anteromedially and the ADMbeing used to cover it laterally. Matrices are usually of human,
porcine, or bovine origin. They have been shown to improve the
aesthetic outcome, reduce implant-related morbiditydsuch as
capsular contracture [28]dimprove tolerance to radiotherapy, and
produce a more natural anatomical reconstruction of the infra-
mammary fold and ﬁnal breast contour [29,30].
Use of ADM allows placement of tissue expanders with greater
intraoperative ﬁll volumes; therefore, fewer expansions are
required before exchange for the permanent implant. In addition,
ADM may have the potential to reduce the rate of encapsulation
[31]. Finally, use of ADM avoids elevation of the serratus anterior,
which was once thought to decrease postoperative pain. However,
a multicenter, blinded, randomized controlled trial did not
demonstrate any reduction in postoperative pain with ADM use
[32].
Nevertheless, several complications may occur due to the
release of the pectoralis major muscle, and physiotherapy rehabil-
itation is frequently required [33]. The detachment of the pectoralis
Fig. 5. Anatomical silicone implant.
Fig. 6. Left mastectomy before reconstruction.
Fig. 7. Left mastectomy post two stage reconstruction.
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muscle can cause prolonged postoperative pain [34]. A new con-
servative surgical technique that preserves the pectoralis major
muscle is possiblewith Braxon®, a non-crosslinked acellular dermal
matrix [35]. This ADM is wrapped around the breast implant and
sutured with absorbable sutures to the superﬁcial surface of the
pectoralis major, avoiding its detachment.5. Breast reconstruction using ﬂaps/autologous tissue
Autologous reconstruction uses the woman's tissue and can be
performed immediately at the time of mastectomy or in a delayed
fashion. Immediate reconstruction potentially exposes the patient
to fewer operations, can save resource costs [35,36], and gives the
patient the best chance of a good aesthetic result [37]. In delayed
reconstruction, mastectomy skin ﬂaps are often scarred and less
compliant [38], and a higher rate of free-ﬂap thrombosis has been
found (AOR, 1.42; overall free ﬂap thrombosis rate 2.4%) [39].
However, similar rates of both major and minor complications have
been reported between patients undergoing either immediate or
delayed reconstruction with a transvers rectus abdomins muscle
(TRAM) free ﬂap [40].
The most favored donor site andmethod of choice in autologous
breast reconstruction is utilization of the lower abdominal tissue
[41] in the form of a TRAM, deep inferior epigastric artery perfo-
rator (DIEP), or superﬁcial inferior epigastric artery (SIEA) ﬂap.
Autologous reconstruction can also be performed using tissue from
the thigh or buttock in the form of transverse upper gracilis (TUG),
superior gluteal artery perforator (SGAP), inferior gluteal artery
perforator (IGAP), or profunda artery perforator (PAP) ﬂaps. Breast
reconstruction using autologous ﬂap tissue allows a natural and
durable result, although ﬂap harvest causes “collateral damage” at
the donor site, including potential surgery-related complications,
scars, contour deformity, and functional impairment. Wound-
related complication rates vary from 30 to 50% in the largest se-
ries [42,43]. Ischemic complications include fat necrosis or ﬂap loss
in free-ﬂap reconstruction. A recent meta-analysis showed that
ischemic complications are higher in DIEP ﬂaps comparedwith free
TRAM ﬂaps [44]. The pedicled TRAM tends to be associated with
more fat necrosis than free abdominal ﬂaps [45,46] and an
increased risk of partial and total ﬂap loss in obese patients [47]. To
decrease these types of complications, especially in “high risk”
patients, a vascular delay procedure can be used in which the
inferior vascular pedicle is ligated 2e3 weeks before reconstruction
[48]. Criticism of the free TRAM ﬂap has been related to morbidity
from sacriﬁcing the rectus muscle at the donor site [49,50]. Patients
reconstructed with a free TRAM ﬂap have decreased abdominal
strength and twice the risk of an abdominal bulge or hernia
compared with DIEP reconstructions [51].
Technology is rapidly progressing and continues to challenge
and exceed expectations, while maintaining considerations for
patient safety and accessibility. Careful preoperative planning of
interventions may be performed making use of new computer
devices [52,53]. The review of comprehensive imaging such as CTA
and MRA can highlight other dominant perforators near potential
donor sites and facilitate consideration of all feasible options for
autologous breast reconstruction, but do not provide physiological
information or ﬂow characteristics. Some of these technologies
serve as an aid to reduce the learning curve, potentially decrease
surgery time and operative stress, and may translate into improved
clinical outcomes [54,55].
6. Autologous fat grafting
Autologous fat grafting (AFG) is an increasingly popular tech-
nique for breast reconstruction [56]. Its main use it to address any
step-off and contour deformities following either implant- or
autologous-based breast reconstruction [57]. Furthermore AFG can
correct any asymmetry with the contralateral breast that can
eventually develop in the late postoperative period following ra-
diation therapy [58]. In literature, there's some debate regarding
the safety of AFG following breast reconstruction for breast cancer;
nevertheless to date there's no clear evidence of cancer recurrence
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The growing popularity of AFG derives from its speciﬁc char-
acteristics. Indeed it's the ideal ﬁller being 100% autologous thus no
graft reaction can be seen [60]. Furthermore its function is more
than simply ﬁlling a defect or modifying a contour but can improve
the texture of the skin, scars and any late chronic degenerative side
effect of radiation therapy [61]. This regenerative potential of AFG
derives mainly from a population of stem cells, the adipose-derived
stem cells (ASCs) localized within the so-called stromal vascular
fraction of the adipose tissue [62e65]. ASCs are multipotent
mesenchymal stem cells that show deﬁnitive stem cell character-
istics such as plastic adherence in culture, ability to maintain
multipotency upon in vitro expansion, and self-renewal capacity
[66e71].
ASCs can be isolated from the harvested adipose tissue by either
mechanical and/or mechanical means [72e76]. Once the pellet of
stem cells is obtained it can be added to the processed lipoaspirates
prior to fat grafting, creating a cell-assisted lipoarpirates [77].
Indeed one of the main drawbacks of AFG is its unpredictable
reabsorption rate of the grafted adipose tissue that seems to be
improved by the adjunction of ASCs [60].
The Coleman technique for AFG is by far the most commonly
used [78,79]. The adipose tissue is inﬁltrated with a tumescent
solution (e.g., Klein solution) [80] and then manually harvested
with 3-mm, blunt-edged, 2- hole cannula connected to a 10-mL
syringe. The lipoaspirate is subsequently centrifuged for 3 min at
3000 rpm in order to isolate the adipose tissue for the oil and
watery fraction and ﬁnally injected. The entire procedure can be
performed under local assisted anesthesia.
7. Timing of reconstruction
Alloplastic reconstruction can be performed concomitantly
with mastectomy (immediate or single-stage reconstruction) or
weeks, months, or years later (delayed or two-stage reconstruc-
tion) [81].
Single-stage reconstruction may have positive psychological
implications compared with delayed reconstruction: decreased
distress, improved freedom of dress, better body image and self-
esteem, decreased anxiety and depression, and improved feelings
of sexual attractiveness and satisfaction. The greatest beneﬁt of
immediate reconstruction may be potentially fewer operations.
Reconstruction of small breasts using skin-sparing mastectomy can
be done with this method. The most suitable patients for this
reconstructionmethod have less ptotic, round-shaped breasts, with
healthy mastectomy ﬂaps and less than 300 g of tissue to be
resected [82e84]. It is difﬁcult to obtain symmetry in single-stage
reconstruction. In addition, the rate of complications such as
infection, skin necrosis and implant exposure are higher in com-
parisonwith two-stage methods. The ﬁnal breast form from single-
stage reconstruction methods is typically smaller and less ptotic
than that from two-stage methods [85].
Delayed reconstruction allows the patient additional time to
consider her restorative options and represents the most
commonly practiced form of breast reconstruction with implants
[86]. In this method, a temporary device called a tissue expander is
placed in a submuscular pocket during the ﬁrst operation. At a later
time, the tissue expander is removed, and breast reconstruction is
completed with a permanent implant. Two-stage reconstruction
has several advantages over the single-stage method. Indeed the
tissue quality overlying the implant improves after the tissue-
expander placement, while re-adjustment of the position of the
permanent implant and manipulation of the inframammary fold
are possible during the second stage, providing a better ﬁnal breast
shape. The period between the ﬁrst and second stage also givestime for the patient and surgeon to deal with treatment matters
such as chemotherapy and radiotherapy.
Tissue expansion/implant-based reconstruction requires
enough of a healthy skin envelope for a tension-free closure. The
native skin and/or muscle envelope may not be adequate to un-
dergo expansion if there are multiple scars or a history of previous
radiation injury, or if there was a large amount of skin resected
during mastectomy. In these cases, the use of an autologous ﬂap
(most commonly, the latissimus dorsi myocutaneous ﬂap) can
provide coverage of the expander and, eventually, the implant.
Patients requiring a salvage mastectomy after failed lumpectomy/
irradiation can beneﬁt from a latissimus dorsi/implant recon-
struction [87]. Furthermore, use of an autologous ﬂap in previously
irradiated breasts appears to reduce the incidence of implant-
related complications [88].
8. Drain management
Drains are typically placed after immediate reconstruction,
especially after axillary dissection, but are rarely placed after
delayed or second-stage reconstruction. In these cases, prior to skin
closure, a closed bulb suction drain is placed over the pectoralis
muscle so that it is not in contact with the implant. Drains are
typically removed when drainage is less than 30 ml in a 24-h
period, with many surgeons removing drains at 7e14 days post-
operation irrespective of output.
9. Radiotherapy and prosthetic breast reconstruction
Postmastectomy radiation therapy (PMRT) is used for tumors
with a size of 5 cm or less and one to three positive nodes [89]. In
general, the timing of radiotherapy is dictated by whether patients
require neoadjuvant chemotherapy [90]. For those requiring neo-
adjuvant chemotherapy, radiation therapy is delivered with the
tissue expander in place, before it is exchanged for the permanent
device. If adjuvant chemotherapy is delivered, radiation can be
delivered either before or after the exchange procedure to the
permanent implant.
Radiation injury usually occurs in two phases, acute and chronic.
The acute phase is characterized by an inﬂammatory reaction that
may consist of swelling, edema, erythema, desquamation, and ul-
ceration [91,92]. Overall, this acute radiation dermatitis occurs in
95% of patients treated with radiation [93].
The chronic phase consist of ﬁbrosis as a reaction to radiation
injury, and it primarily effects the skin and subcutaneous breast
tissue. The signs and symptoms include varying degrees of per-
manent skin retraction and induration, chest and shoulder pain,
and restricted arm and neck movement [94]. Radiation-induced
ﬁbrosis typically presents several months after radiotherapy and
may progress for several years. Rates of capsular contracture have
varied from 29% [95] to 68% [96] in patients with radiotherapy,
compared with 10% [97] to 40% [98] of those without radiotherapy.
The risk of signiﬁcant capsular contracture (Baker Grade III or IV)
has also been found to be higher in irradiated breasts [99,100].
10. Complications
10.1. Risk factors
Patient selection begins with a physical examination and in-
cludes consideration of co-morbidities (diabetes, hypertension,
immunodeﬁciency), tobacco use history, body habitus, and breast
characteristics (fat versus glandular type). The occurrence of
adverse events can be directly attributed to a variety of factors
including elevated BMI, tobacco use, and poorly controlled diabetes
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delayed healing, reconstructive failure, and increased rates of
reoperation [102,103]. Nicotine is a powerful vasoconstrictor and
will impact circulation at the level of the capillaries and small
vessels. By avoiding tobacco, wound-related complications could be
reduced as much as threefold, from 23.5% to 7.7% [104].
Poorly controlled diabetes mellitus (types I and II) is a known
factor associated with compromised healing as well [105]. Hyper-
glycemic states can interfere with normal wound healing and
contribute to increased rates of incisional dehiscence and soft tis-
sue infection, which can have signiﬁcant consequences, especially
in obese patients havingmastectomy. Ideally, serum glucose should
be less than 200 mg/dl, and urine glucose should be absent.
When considering breast reconstruction with prosthetic de-
vices, obese and morbidly obese women are at risk for adverse
events. Women with a BMI <30 are usually considered good can-
didates, whereas women with a BMI >40 are not because of
increased incidences of seroma, compromised healing, infection,
and poor cosmetic outcome [106].
Mammary hypertrophy in and of itself is not a contraindication
to prosthetic breast reconstruction; however, there are several
strategies that can increase the likelihood of a successful outcome.
Most women with mammary hypertrophy will have large mas-
tectomy skin excision patterns because traditional skin or nipple
sparing is usually not an option. In these cases, we can use onco-
plastic breast techniques such as superior/inferior pedicle mam-
moplasty with an inverted T/J scar.10.2. Infections
Prosthesis-based breast surgery, both reconstructive and
aesthetic, is associated with an even higher infection risk, and
postoperative prophylactic antibiotics are routinely prescribed
[107]. Breast implant infections involve 2e2.5% of patients and
represent the leading cause of morbidity after reconstructive and
aesthetic surgery [108]. Although antibiotic prophylaxis has been
shown by several studies to prevent surgical site infection,
extended antibiotic prophylaxis may lead to systemic side effects,
super-infection, and the development of resistant organisms. We
feel that extended systemic antibiotic prophylaxis (24 h post-
operatively) can signiﬁcantly reduce infection risk, especially in
implant breast reconstruction. Topical antibiotic irrigation may
decrease capsular contraction risk, but it might not reduce the
infection rate. A cephalosporin is generally recommended for
antibiotic prophylaxis to cover for the most commonly identiﬁed
implant-associated bacteria. Antibiotic prophylaxis may be
extended postoperatively in cases with certain individual risk
factors.10.3. Seroma
The incidence of seroma after prosthetic breast reconstruction
varies from 0.2 to 20% [109e115]. Obesity and acellular dermal
matrix use have been implicated as speciﬁc risk factors [116]. A
number of variables purport to contribute to seroma formation,
including the creation of a large, irregular dead space by mastec-
tomy; insertion of a foreign body; movement of the chest wall;
lymphatic disruption; and the post-operative inﬂammatory reac-
tion [117,118]. Given these pathophysiologic insultsdall in the
setting of a relatively hypovascular milieudseroma is not unex-
pected. Whether seroma serves as a nidus for infection leading to
implant loss, or is simply a marker of poor wound healing and
occult infection; indeed seroma seems to correlate with higher
subsequent complications [119].10.4. Implant exposure
In cases of immediate reconstruction, tension and mastectomy
ﬂap overdissection are associated with skin ﬂap necrosis at the
incision site. One of the beneﬁts of complete submuscular place-
ment is that local wound care is all that is necessary provided skin
necrosis is minor and the underlying muscle is healthy. When ra-
diation over an expanded implant is poorly titrated, full thickness
skin loss remains a possibility. In severe cases, the expander may
need to be removed. When the underlying device is a tissue
expander, continued expansion to the desired volume or to match a
contralateral implant may not be possible as volume must be
removed to allow healing subsequent to any necessary debride-
ment. In the event of permanent implant exposure, debridement
and immediate wound closure is necessary. If enough skin is lost so
that primary closure is not possible, the implant should be removed
and additional skin transferred by autologous reconstruction.
10.5. Anaplastic large cell lymphoma
Recently, there have been concerns raised about anaplastic large
cell lymphoma (ALCL) associated with breast implants. The re-
ported cases involved various lymphoma subtypes with the ma-
jority being ALCL, of which 66 were conﬁrmed as ALK negative.
However, there was no association with any particular implant
type. The more aggressive cases and reported low death rate
appeared to be related to the presence of breast masses at the time
of presentation rather than effusion. The remaining reports were
occasional case reports of T-cell lymphoma, follicular lymphoma,
marginal zone B-cell lymphoma, primary effusion lymphoma, and
lymphoplasmacytic lymphoma [120].
11. Conclusion
Breast reconstruction has evolved in time as new surgical
techniques developed along with neo-/adjuvant treatments. Breast
reconstruction itself can basically be classiﬁed into four categories:
implant- and expander-based breast reconstruction, ﬂap-based
breast reconstruction (using vascularized autologous tissue), a
combination of both (ﬂap and implant), and breast reconstruction
using fat grafting. Nevertheless, fat grafting is predominantly used
to reﬁne post-reconstructive asymmetries. Breast reconstruction
can be either performed at the time of surgery in immediate setting
or delayed. Finally alloplastic breast reconstruction can be further
performed in immediate settings as one- or two-stage approach
when there's the need for tissue expansion.
Alloplastic (either as direct-to-implant or implant/tissue
expander-based) breast reconstruction recently surpassed autolo-
gous one as the most employed reconstructive approach. Indeed
advocates of alloplastic reconstruction highlight the main draw-
back of autologous one as: longer time operative time, longer
hospital stay, higher donor site morbidity and further scar.
Conversely alloplastic reconstructions, expose patients to less sur-
gical risk, fewer scars, less donor site morbidity, and fewer irre-
versible consequences. Nevertheless autologous reconstruction can
achieve is a one-stage reconstruction strategy that can achieve a
more natural cosmetic outcome and is the only one able to
reconstruct large breast when patients do not want contralateral
matching surgery.
This vary of reconstructive strategy should be all part of the
armamentarium of breast surgeons, which should be able to
discuss with the patients the best approach for her. Indeed breast
reconstruction should be individualized for each patient by taking
into consideration not only tumor oncology, neo-/adjuvant treat-
ments, and genetic predisposition, but also the patient's condition
M. Gardani et al. / Annals of Medicine and Surgery 21 (2017) 96e104102and wishes regarding its timing. Thus offering patients an oppor-
tunity for breast reconstruction is an important component of
breast cancer treatment. Despite the complex decision-making
process that includes many different aspects, the overall number
of breast reconstructions has recently increased considerably.
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